Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a deeper understanding of their complex mechanism of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Oncol
Autori principali: Dimopoulos, Konstantinos, Søgaard Helbo, Alexandra, Fibiger Munch‐Petersen, Helga, Sjö, Lene, Christensen, Jesper, Sommer Kristensen, Lasse, Asmar, Fazila, Hermansen, Niels Emil Ulrich, O'Connel, Casey, Gimsing, Peter, Liang, Gangning, Grønbæk, Kirsten
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5792743/
https://ncbi.nlm.nih.gov/pubmed/29130642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12157
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi